European Commission Grants Marketing Authorisation for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma
Foster City, CA, 19 September 2014 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing…